Dopamine: A marker of psychosis and final common driver of schizophrenia psychosis

American Journal of Psychiatry

Volumn 168, Issue 12, 2011, Pages 1239-1240

  Henn, Fritz A ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; CHLORPROMAZINE; DOPAMINE;

COGNITIVE THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; ELECTROENCEPHALOGRAM; HIGH RISK PATIENT; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RISK FACTOR; SCHIZOPHRENIA; SOCIAL SUPPORT; BIOSYNTHESIS; BRAIN; FEMALE; MALE; METABOLISM; NOTE; PSYCHOSIS;

BRAIN; DOPAMINE; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS;

EID: 84857073674     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11091346     Document Type: Editorial

References (11)

1. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmcol Toxicol 1963; 20:140-144
2. Seeman P, Lee T: Antipsychotic drugs direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188:1217-1219
3. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
4. Carpenter WT: Anticipating DSM: should psychosis risk become a diagnostic class? Schizophr Bull 2009; 35:841-843
5. Woods SW, Walsh BC, Saksa JR, McGlashan TH: The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010; 123:199-207
6. Marshall M, Rathbone J: Early intervention for psychosis. Cochrane Database Syst Rev 2011; 6:CD004718
7. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P: Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011; 168:1311-1317
8. Yung AR, Yuen HP, Berger G, Francey S, Hunag TC, Nelson B, Phillips L, McGorry P: Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk. Schizophr Bull 2007; 33:673-681 (Pubitemid 47343718)
9. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidmn LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R: At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011; 168:800-805
10. Koutsouleris N, Gaser C, Bottlender R, Davatzikos C, Decker P, Jager M, Schmitt G, Reiser M, Moeller H-J, Meisenzahl EM: Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. Schizophr Res 2010; 123:175-187
11. Zimmermann R, Gschwandtner U, Wilhelm FH, Pflueger MO, Riecher-Röessler A, Fuhr P: EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophr Res 2010; 123:217-224